GenMont Biotech Incorporation (TWSE: 3164)
Health Care · Biotechnology · TW
NT$15.90
-0.62% today · -19.7% 1Y
GenMont Biotech Incorporation (TWSE: 3164) operates in the Biotechnology industry within the Health Care sector. The company is valued at $42.95M and employs 147 people.
Over the last twelve months the share price has lost 19.7%, trading between 15.35 and 20.45.
Tweenvest scores GenMont Biotech Incorporation across four factors: quality 72/100, value 63/100, growth 37/100, dividend 37/100. Its strongest factor is quality.
3164 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $42.95M
- Revenue (TTM)
- $12.01M
- P/E
- 19.90
- EPS
- 0.80
- Dividend yield
- 5.03%
- Beta (5Y)
- 0.07
- 52-week high
- NT$20.45
- 52-week low
- NT$15.35
- Avg volume (3M)
- —
- Shares outstanding
- 86.01M
- Employees
- 147
- Next earnings
- —
About GenMont Biotech Incorporation
Based in Taiwan, GenMont Biotech Incorporation is primarily engaged in the comprehensive process of developing, manufacturing, and marketing functional probiotic products. Beyond its core offerings, the company also provides specialized probiotic formulations. It extends its services to include original formula design and production for health-oriented food items, as well as supplying relevant manufacturing equipment. Additionally, GenMont Biotech actively collaborates on the research, production, and clinical evaluation of a variety of other products. The company was established in 2000 and has its headquarters situated in Tainan City, Taiwan.
- ISIN
- TW0003164000
- Founded
- 2000
- Listed since
- Sep 19, 2008
- Exchange
- Taiwan Stock Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.